A Phase I Study of CDX-622
Completed · Phase 1
Conditions studied: Healthy Participants
In brief
This is a study to determine the safety of CDX-622 in healthy participants.
Key facts
- Study ID
- NCT06650761
- Run by
- Celldex Therapeutics
- People needed
- 85
- Starts
- 2024-11-01
- Expected to finish
- 2026-04-24
- Last updated by the study team
- 2026-05-04
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Celerion, Inc. — Tempe, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.